| Name | Title | Contact Details |
|---|---|---|
Robin Smith |
Chief Executive Officer | Profile |
Ingrid Smith |
Vice President of Human Resources | Profile |
Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.
Shiru is in the vanguard of startups that are discovering the molecular blueprints of nature — then using new ways to reconstruct the world`s most popular and pleasing ingredients without the need for animals or other unsustainable sources.
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.
LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic and acquired diseases.
Ariana is a spin-off of the prestigious Pasteur Institute offering a unique and powerful association rules-based analytical approach to clinical datasets and biomarker discovery that is complementary to statistical analysis.